Peptides Studied in Muscle Biology Research

Overview: Muscle Biology Research Peptides

Several classes of research peptides have been studied in the context of skeletal muscle biology, covering mechanisms including: pituitary GH secretion, IGF-1 axis activity, myostatin pathway inhibition, satellite cell activation, and muscle tissue repair following injury.

This guide organizes these compounds by mechanistic class and summarizes the preclinical research for each. All compounds listed are available from Rainbow Peptide for legitimate research purposes only.

Important note on scope: "Muscle growth" in a research context refers to documented effects on skeletal muscle mass, fibre cross-sectional area, protein synthesis rates, or satellite cell activation in animal models. These findings do not imply any approved use, and none of these compounds are approved by the FDA or any regulatory body for therapeutic or performance enhancement purposes.

GH Secretagogues: GHRP-6, GHRP-2, Ipamorelin, Hexarelin

Growth hormone releasing peptides (GHRPs) stimulate GH release from the anterior pituitary by binding the ghrelin receptor (GHSR-1a). This triggers a GH pulse which, in turn, stimulates hepatic and peripheral IGF-1 production.

GHRP-6

The original GHRP compound, GHRP-6 (His-DTrp-Ala-Trp-DPhe-Lys-NH2) has been studied extensively in both animal and human clinical pharmacology. It produces robust GH pulses in rodent models and has been shown to increase lean body mass in GH-deficient models. Notable side effect in research: appetite stimulation via ghrelin pathway (studied as both a feature and limitation depending on model).

GHRP-2

A second-generation GHRP with higher potency than GHRP-6 at equivalent doses. GHRP-2 has been tested in human Phase I/II studies for GH deficiency and demonstrated reliable pulsatile GH secretion with fewer GI side effects than GHRP-6 in clinical pharmacology studies.

Ipamorelin

Ipamorelin is a highly selective GHRP that stimulates GH release with minimal effect on cortisol, prolactin, or ACTH — making it the preferred secretagogue in many research protocols where isolating GH-specific effects is important. Multiple animal studies have documented lean mass increases and fat mass reductions.

Hexarelin

The most potent of the first-generation GHRPs. Hexarelin also has documented cardioprotective effects in cardiac injury models independent of its GH-releasing activity, through direct binding to CD36 scavenger receptor on myocardial cells.

GHRH Analogues: CJC-1295, Sermorelin, Tesamorelin

GHRH analogues mimic endogenous growth hormone-releasing hormone, stimulating the pituitary through the GHRH receptor (GHRHR). They produce a more physiological, wave-like GH release pattern compared to GHRPs.

CJC-1295

CJC-1295 (with DAC — drug affinity complex) achieves an extended half-life through covalent binding to circulating albumin via its C-terminal lysine. This produces sustained elevation of GH and IGF-1 levels in animal models over several days from a single dose — distinct from the pulsatile pattern of shorter-acting GHRH analogues.

Sermorelin

Sermorelin (GRF 1-29-NH2) is the shortest functional GHRH fragment studied. It has the most clinical trial history of all GHRH analogues, having been FDA-approved (as Geref) for paediatric GH deficiency diagnosis before being withdrawn from the market. Extensively studied in lean mass and GH restoration research.

Tesamorelin

Tesamorelin (Egrifta) is the only GHRH analogue currently FDA-approved for any indication (lipodystrophy associated with HIV antiretroviral therapy). Its approval demonstrates the highest level of clinical evidence for any GHRH analogue in body composition effects.

Tissue Repair Peptides: BPC-157 & TB-500

BPC-157 and TB-500 (Thymosin Beta-4 fragment) are studied for their effects on muscle tissue repair following injury rather than primary muscle growth mechanisms.

BPC-157 has over 20 published studies specifically in muscle crush injury models, demonstrating accelerated recovery of muscle architecture and function in rodents. Its mechanism involves VEGF upregulation, fibroblast activation, and NO system modulation.

TB-500 modulates actin polymerization dynamics by sequestering G-actin, reducing F-actin formation. This has downstream effects on cell migration and tissue remodeling that have been studied in cardiac, muscle, and dermal injury models.

For researchers studying exercise-induced muscle damage recovery models, BPC-157 and TB-500 represent complementary mechanisms: BPC-157 for angiogenesis and connective tissue healing; TB-500 for cytoskeletal repair and cell migration.

Myostatin Inhibitors: ACE-031 & Research Context

Myostatin (GDF-8) is a TGF-β family member that negatively regulates skeletal muscle mass. Myostatin knockout mice develop dramatically increased muscle mass (the "double-muscled" phenotype), establishing myostatin inhibition as one of the most potent interventions for muscle hypertrophy in rodent models.

ACE-031 (ActRIIB-Fc) is a fusion protein of the activin receptor IIB extracellular domain with Fc. It acts as a "ligand trap," binding myostatin, activin A/B, GDF-11, and other TGF-β family members to block their signalling. Phase II trials in Duchenne MD demonstrated lean mass increases before discontinuation due to adverse events in a non-muscle tissue context.

The body of myostatin inhibitor research illustrates both the potential and complexity of targeting this pathway — with significant lean mass effects in preclinical models but translational challenges in clinical development.

IGF-1 Axis Research

The insulin-like growth factor 1 (IGF-1) axis is downstream of GH secretion and is considered the primary mediator of GH's muscle anabolic effects. IGF-1 LR3 (a long-acting recombinant IGF-1 analogue) is studied for direct IGF-1R activation independent of GH pulsatility, producing skeletal muscle hypertrophy and satellite cell activation in rodent studies.

Notably, MOTS-c (a mitochondria-derived peptide) has also been linked to IGF-1 pathway interactions in some preclinical studies, making it of interest in combination with GH secretagogue research protocols.

Peptide Comparison Table